Related Experiment Video

Updated: Oct 4, 2025

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.5K

Antibody-Pattern Recognition Receptor Agonist Conjugates: A Promising Therapeutic Strategy for Cancer

Jian Xu1, Xiang Li2, Yue Du3

  • 1Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Advanced Biology
|February 5, 2022
PubMed

Insights

Antibody-drug conjugates (ADCs) offer targeted cancer therapy by linking antibodies to drugs. New antibody-PRR agonist conjugates show promise for improved efficacy and reduced toxicity in cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Antibody-drug conjugates (ADCs) are advanced therapeutics combining monoclonal antibodies with cytotoxic payloads for targeted drug delivery.
  • ADCs have demonstrated efficacy in treating various cancers, with 12 currently approved by the U.S. Food and Drug Administration.
  • Expanding ADC applications involves novel formats like pattern recognition receptor (PRR) agonist-based ADCs.

Purpose of the Study:

  • To review the current landscape of antibody-PRR agonist conjugates for cancer therapy.
  • To discuss the potential and future perspectives of this emerging therapeutic strategy.

Main Methods:

  • Literature review of existing research on ADCs and PRR agonists.
  • Analysis of the structural advantages of antibodies for targeted delivery of PRR agonists.
  • Evaluation of therapeutic efficacy and toxicity profiles.

Main Results:

  • Antibody-mediated delivery of PRR agonists specifically targets tumor areas.
  • This targeted approach enhances therapeutic efficacy.
  • Systemic toxicity is minimized compared to conventional treatments.

Conclusions:

  • Antibody-PRR agonist conjugates represent a promising advancement in cancer therapy.
  • Their unique structure facilitates targeted delivery, improving treatment outcomes.
  • Further research and development are warranted to fully realize their potential in oncology.
Keywords:
antibody-drug conjugatecancerpattern recognition receptor agonisttargeted therapies

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.7K
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.1K